Skip to main content
Heart FailureHeart and circulationDevice

What this study is

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

What's being tested

  • Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System

    Intervention · DEVICE

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.

  • OPTIMIZER™ Smart Mini System

    Intervention · DEVICE

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.

Study details

Official title
Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction
Sponsor
Impulse Dynamics
Conditions
Heart Failure · Heart Failure With Preserved Ejection Fraction · Heart Failure With Mid Range Ejection Fraction · Heart Failure With Moderately Reduced Ejection Fraction · Diastolic Heart Failure
Enrolling
1,500 people
Starts
2022-02-03
Est. completion
2029-02-01
Design
Quadruple-blind, randomized, parallel groups
Record
View on ClinicalTrials.gov ↗